A Novel Estimation of the Relative Economic Value in Terms of Different Chronic Hepatitis B Treatment Options

Jun Yong Park, Jeong Heo, Tae Jin Lee, Hyung Joon Yim, Jong Eun Yeon, Young Suk Lim, Min Jeong Seo, Sang Hoon Ahn, Myung Seok Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Prescribers, payors and healthcare decision-makers are increasingly examining the value of treatments. This study aims at analyzing economic value of chronic hepatitis B (CHB) treatment options, which are available in Korea. Methods: CHB infection was simulated using a health-state transition model with disease states defined as mild disease (Ishak F0/F1), fibrosis (F2/F3/F4), advanced fibrosis/cirrhosis (>F4), and complicated disease states (decompensated cirrhosis, hepatocellular carcinoma, liver transplant and death) based on available natural history data. The value of treatment-specific attributes on disease progression/regression was estimated based on published data in terms of events and costs avoided. 5-year treatment duration was assumed except for treatment initiation. Primary model output is the estimated cost savings of entecavir per patient per day of treatment versus the comparator in question for a given CHB patient. Results: The simulation of treating with entecavir versus no treatment predicted improved clinical outcomes for entecavir-treatment patients. In the long term, these clinical benefits translate into cost savings of $3.10 per day of treatment. In naive patient treatment, daily cost savings of using entecavir versus lamivudine or telbivudine was estimated at $2.89 and $1.72, respectively. In the case of suboptimal responders who pre-treated with lamivudine, daily cost saving for patients switching to entecavir was $1.38 per day of treatment compared to patients maintaining on lamivudine. Conclusions: Entecavir exhibits characteristics of a favourable CHB treatment, which directly translates into economic and therapeutic value as opposed to either no treatment or alternative strategies.

Original languageEnglish
Article numbere57900
JournalPLoS One
Volume8
Issue number3
DOIs
Publication statusPublished - 2013 Mar 11

Fingerprint

chronic hepatitis B
Chronic Hepatitis B
economic valuation
Economics
cost effectiveness
Lamivudine
Patient treatment
Costs
fibrosis
Cost Savings
Therapeutics
Fibrosis
liver transplant
Transplants
hepatoma
natural history
disease course
Liver
health services
Korean Peninsula

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

A Novel Estimation of the Relative Economic Value in Terms of Different Chronic Hepatitis B Treatment Options. / Park, Jun Yong; Heo, Jeong; Lee, Tae Jin; Yim, Hyung Joon; Yeon, Jong Eun; Lim, Young Suk; Seo, Min Jeong; Ahn, Sang Hoon; Lee, Myung Seok.

In: PLoS One, Vol. 8, No. 3, e57900, 11.03.2013.

Research output: Contribution to journalArticle

Park, Jun Yong ; Heo, Jeong ; Lee, Tae Jin ; Yim, Hyung Joon ; Yeon, Jong Eun ; Lim, Young Suk ; Seo, Min Jeong ; Ahn, Sang Hoon ; Lee, Myung Seok. / A Novel Estimation of the Relative Economic Value in Terms of Different Chronic Hepatitis B Treatment Options. In: PLoS One. 2013 ; Vol. 8, No. 3.
@article{a7e41383a5924c0ab12d7d3f43b81a4f,
title = "A Novel Estimation of the Relative Economic Value in Terms of Different Chronic Hepatitis B Treatment Options",
abstract = "Background: Prescribers, payors and healthcare decision-makers are increasingly examining the value of treatments. This study aims at analyzing economic value of chronic hepatitis B (CHB) treatment options, which are available in Korea. Methods: CHB infection was simulated using a health-state transition model with disease states defined as mild disease (Ishak F0/F1), fibrosis (F2/F3/F4), advanced fibrosis/cirrhosis (>F4), and complicated disease states (decompensated cirrhosis, hepatocellular carcinoma, liver transplant and death) based on available natural history data. The value of treatment-specific attributes on disease progression/regression was estimated based on published data in terms of events and costs avoided. 5-year treatment duration was assumed except for treatment initiation. Primary model output is the estimated cost savings of entecavir per patient per day of treatment versus the comparator in question for a given CHB patient. Results: The simulation of treating with entecavir versus no treatment predicted improved clinical outcomes for entecavir-treatment patients. In the long term, these clinical benefits translate into cost savings of $3.10 per day of treatment. In naive patient treatment, daily cost savings of using entecavir versus lamivudine or telbivudine was estimated at $2.89 and $1.72, respectively. In the case of suboptimal responders who pre-treated with lamivudine, daily cost saving for patients switching to entecavir was $1.38 per day of treatment compared to patients maintaining on lamivudine. Conclusions: Entecavir exhibits characteristics of a favourable CHB treatment, which directly translates into economic and therapeutic value as opposed to either no treatment or alternative strategies.",
author = "Park, {Jun Yong} and Jeong Heo and Lee, {Tae Jin} and Yim, {Hyung Joon} and Yeon, {Jong Eun} and Lim, {Young Suk} and Seo, {Min Jeong} and Ahn, {Sang Hoon} and Lee, {Myung Seok}",
year = "2013",
month = "3",
day = "11",
doi = "10.1371/journal.pone.0057900",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - A Novel Estimation of the Relative Economic Value in Terms of Different Chronic Hepatitis B Treatment Options

AU - Park, Jun Yong

AU - Heo, Jeong

AU - Lee, Tae Jin

AU - Yim, Hyung Joon

AU - Yeon, Jong Eun

AU - Lim, Young Suk

AU - Seo, Min Jeong

AU - Ahn, Sang Hoon

AU - Lee, Myung Seok

PY - 2013/3/11

Y1 - 2013/3/11

N2 - Background: Prescribers, payors and healthcare decision-makers are increasingly examining the value of treatments. This study aims at analyzing economic value of chronic hepatitis B (CHB) treatment options, which are available in Korea. Methods: CHB infection was simulated using a health-state transition model with disease states defined as mild disease (Ishak F0/F1), fibrosis (F2/F3/F4), advanced fibrosis/cirrhosis (>F4), and complicated disease states (decompensated cirrhosis, hepatocellular carcinoma, liver transplant and death) based on available natural history data. The value of treatment-specific attributes on disease progression/regression was estimated based on published data in terms of events and costs avoided. 5-year treatment duration was assumed except for treatment initiation. Primary model output is the estimated cost savings of entecavir per patient per day of treatment versus the comparator in question for a given CHB patient. Results: The simulation of treating with entecavir versus no treatment predicted improved clinical outcomes for entecavir-treatment patients. In the long term, these clinical benefits translate into cost savings of $3.10 per day of treatment. In naive patient treatment, daily cost savings of using entecavir versus lamivudine or telbivudine was estimated at $2.89 and $1.72, respectively. In the case of suboptimal responders who pre-treated with lamivudine, daily cost saving for patients switching to entecavir was $1.38 per day of treatment compared to patients maintaining on lamivudine. Conclusions: Entecavir exhibits characteristics of a favourable CHB treatment, which directly translates into economic and therapeutic value as opposed to either no treatment or alternative strategies.

AB - Background: Prescribers, payors and healthcare decision-makers are increasingly examining the value of treatments. This study aims at analyzing economic value of chronic hepatitis B (CHB) treatment options, which are available in Korea. Methods: CHB infection was simulated using a health-state transition model with disease states defined as mild disease (Ishak F0/F1), fibrosis (F2/F3/F4), advanced fibrosis/cirrhosis (>F4), and complicated disease states (decompensated cirrhosis, hepatocellular carcinoma, liver transplant and death) based on available natural history data. The value of treatment-specific attributes on disease progression/regression was estimated based on published data in terms of events and costs avoided. 5-year treatment duration was assumed except for treatment initiation. Primary model output is the estimated cost savings of entecavir per patient per day of treatment versus the comparator in question for a given CHB patient. Results: The simulation of treating with entecavir versus no treatment predicted improved clinical outcomes for entecavir-treatment patients. In the long term, these clinical benefits translate into cost savings of $3.10 per day of treatment. In naive patient treatment, daily cost savings of using entecavir versus lamivudine or telbivudine was estimated at $2.89 and $1.72, respectively. In the case of suboptimal responders who pre-treated with lamivudine, daily cost saving for patients switching to entecavir was $1.38 per day of treatment compared to patients maintaining on lamivudine. Conclusions: Entecavir exhibits characteristics of a favourable CHB treatment, which directly translates into economic and therapeutic value as opposed to either no treatment or alternative strategies.

UR - http://www.scopus.com/inward/record.url?scp=84874915246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874915246&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0057900

DO - 10.1371/journal.pone.0057900

M3 - Article

C2 - 23536775

AN - SCOPUS:84874915246

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - e57900

ER -